LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced the closing of an underwritten
registered public offering of 1,150,000 shares of its common stock at a
price to the public of $190.00 per share. The shares of common stock
issued in the offering included 150,000 shares of common stock issued
upon the exercise in full by the underwriters of their option to
purchase additional shares. The net proceeds from the offering were
approximately $205 million, after deducting the underwriting discount
and estimated offering expenses payable by the Company.
BofA Merrill Lynch and J.P. Morgan acted as lead book-running managers
and Citigroup acted as joint book-running manager for the offering.
Leerink Partners LLC and Cowen and Company, LLC acted as co-managers for
the offering.
The offering was made pursuant to an automatically effective shelf
registration statement filed with the Securities and Exchange Commission
on January 20, 2015. A final prospectus supplement was filed with the
Securities and Exchange Commission and forms a part of the effective
registration statement. Copies of the final prospectus supplement and
the accompanying prospectus relating to the offering may be obtained by
contacting BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn:
Prospectus Department, email: dg.prospectus_requests@baml.com;
J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866)
803-9204; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, phone (800) 831-9146.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
Contact: